Surrozen (NASDAQ:SRZN) Major Shareholder Acquires $110,404.77 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 5,523 shares of the stock in a transaction dated Wednesday, January 14th. The shares were bought at an average cost of $19.99 per share, with a total value of $110,404.77. Following the transaction, the insider directly owned 999,429 shares of the company’s stock, valued at $19,978,585.71. This represents a 0.56% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 13th, Group Gp Lp Column III acquired 12,470 shares of Surrozen stock. The stock was bought at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III bought 15,100 shares of Surrozen stock. The stock was bought at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III bought 30,884 shares of Surrozen stock. The shares were purchased at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The stock was purchased at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III purchased 315,457 shares of Surrozen stock. The stock was purchased at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

SRZN stock opened at $20.00 on Friday. The stock has a market capitalization of $171.40 million, a P/E ratio of -0.90 and a beta of 0.58. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94. The business has a 50-day moving average of $18.70 and a 200-day moving average of $13.95.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The firm had revenue of $0.98 million during the quarter. Equities analysts expect that Surrozen, Inc. will post -8.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Trading of Surrozen

A number of large investors have recently added to or reduced their stakes in SRZN. Stempoint Capital LP grew its position in shares of Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares during the period. Stonepine Capital Management LLC lifted its stake in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after purchasing an additional 20,247 shares during the last quarter. Vanguard Group Inc. grew its holdings in Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares during the period. Acuta Capital Partners LLC grew its holdings in Surrozen by 5.0% during the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after purchasing an additional 8,415 shares during the period. Finally, Braidwell LP acquired a new position in Surrozen during the second quarter worth approximately $1,252,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.